Managing Ectopic Pregnancy

Documents to Request

• Serial β-hCG values with dates and times
• Transvaginal ultrasound reports (current and prior)
• CBC, type and screen, coagulation studies
• CMP (renal and liver function — required for methotrexate eligibility)
• Prior operative reports (tubal surgery, prior ectopic management)
• Pathology reports (if prior ectopic was treated surgically)

Step 1: Apply the Diagnostic Algorithm

β-hCG and the Discriminatory Zone

The discriminatory zone is the β-hCG level above which a viable IUP should be visible on TVUS:

• Discriminatory level: 3,500 IU/L (institutional range: 1,500–3,500 IU/L)
• Above discriminatory zone + no IUP on TVUS = abnormal pregnancy (ectopic or failed IUP)
• Below discriminatory zone + no IUP = pregnancy of unknown location (PUL) → serial β-hCG trending required

Expected β-hCG Rise in Normal IUP

• Early viable IUP: β-hCG rises by at least 53% in 48 hours (minimum normal rise, per ACOG)
• The traditional "doubling time of 48 hours" applies to early pregnancies (β-hCG < 10,000)
• Slower rise may still be normal; < 53% rise in 48 hours is abnormal and suggests ectopic or nonviable IUP

β-hCG Decline Patterns

• After completed miscarriage: β-hCG should decline by ≥ 21–35% in 48 hours
• Slower than expected decline suggests retained products or ectopic
• Plateau (neither rising nor falling adequately) is concerning for ectopic

Decision Matrix

Step 2: Methotrexate (Medical Management)

Eligibility Criteria for Methotrexate

Methotrexate Protocols

Post-methotrexate monitoring:

• Weekly β-hCG until < 5 IU/L
• Avoid NSAIDs, folate supplements, alcohol, and intercourse until resolved
• Warn about transient β-hCG rise between days 1–4 (expected, not treatment failure)
• Watch for treatment failure signs: increasing pain, hemodynamic change, rising β-hCG after day 7

Step 3: Surgical Management

Indications for Surgery

• Hemodynamic instability (ruptured ectopic)
• Contraindication to methotrexate
• Failed methotrexate (rising β-hCG after day 7 of second dose)
• Patient preference
• Fetal cardiac activity on ultrasound
• β-hCG > 5,000 IU/L (higher failure rate with medical management)

Surgical Options

Post-surgical:

• Follow β-hCG weekly to < 5 IU/L (persistent ectopic tissue requires retreatment in 5–20% of salpingostomy cases)
• RhoGAM if Rh-negative (50 mcg if < 12 weeks, 300 mcg if ≥ 12 weeks)
• Pathology confirmation of ectopic tissue

Step 4: Special Situations

Heterotopic Pregnancy

• Coexisting IUP + ectopic; incidence is 1:30,000 naturally but up to 1:100 with ART
• Methotrexate is contraindicated (would harm the IUP)
• Treatment: surgical removal of ectopic with preservation of IUP

Interstitial (Cornual) Ectopic

• Located in intramural portion of the tube
• Higher rupture risk with more severe hemorrhage
• May present later (up to 12–16 weeks) due to myometrial distensibility
• Surgical: cornual resection or cornuostomy; consider uterine artery embolization

Cesarean Scar Ectopic

• Implantation within the cesarean scar niche
• Increasing incidence with rising cesarean rates
• Management: methotrexate, uterine artery embolization, hysteroscopic resection, or laparotomy

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the β-hCG trend documented with at least two values, dates, and calculated % change?
2. Is the discriminatory zone applied correctly — and does the action match the scenario?
3. Are methotrexate eligibility criteria checked before recommending medical management?
4. Is Rh status addressed with RhoGAM administered or planned if Rh-negative?
5. Is the follow-up plan explicit — serial β-hCG schedule, return precautions, and failure criteria?

Quality Audit

• Quantitative β-hCG documented with date, time, and serial values
• β-hCG trend calculated (% rise or decline in 48 hours)
• Discriminatory zone defined (institutional threshold stated)
• TVUS findings documented (IUP present/absent, adnexal mass, free fluid)
• Hemodynamic status documented
• Risk factors for ectopic documented
• Methotrexate eligibility criteria systematically checked (all elements)
• Methotrexate protocol specified (single-dose, two-dose, or multi-dose) with dosing
• Post-methotrexate monitoring schedule documented
• Surgical indication documented (if operative management chosen)
• Procedure type documented (salpingostomy vs. salpingectomy) with rationale
• Rh status documented and RhoGAM administered/planned
• Pathology confirmation of ectopic tissue documented (surgical cases)
• Patient counseled on ectopic precautions (pain, bleeding, return to ED)
• β-hCG follow-up schedule documented until < 5 IU/L

Guidelines

1. Never diagnose ectopic based on a single β-hCG — serial values and ultrasound findings are required for diagnosis (unless ultrasound shows definitive extrauterine pregnancy with cardiac activity).
2. The discriminatory zone is a guideline, not an absolute — multiple gestations and early IUPs may not be visible at the traditional threshold; use caution before intervening on a desired pregnancy.
3. A rising β-hCG does not exclude ectopic — ectopic pregnancies can show normal-appearing rises in up to 21% of cases.
4. Methotrexate is not risk-free — it requires reliable patient follow-up; do not administer if the patient cannot return for serial monitoring.
5. Ruptured ectopic is a surgical emergency — hemodynamic instability with a positive pregnancy test and free fluid mandates immediate operative intervention without waiting for β-hCG trends.
6. Salpingectomy is preferred when the contralateral tube is healthy — it eliminates the risk of persistent ectopic and recurrence in the same tube.
7. Follow β-hCG to zero after ANY ectopic management — persistent trophoblastic tissue occurs in 5–20% of salpingostomy cases and requires surveillance.
8. Always give RhoGAM to Rh-negative patients — ectopic pregnancy is a sensitizing event.